Trials / Recruiting
RecruitingNCT04821843
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cohort Study of Neoadjuvant Treatment Modalities for Esophageal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.
Conditions
- Esophageal Cancer
- Chemotherapy Effect
- Chemoradiation
- Surgery
- Targeted Therapy
- Immunotherapy
- Esophagogastric Juction Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Platinum based chemotherapy | q1-3W according to physician's preference |
| DRUG | Paclitaxel based chemotherapy | q1-3W according to physician's preference |
| RADIATION | Radiotherpay | 40-50Gy/1.8-2.2Gy/20-25f |
| PROCEDURE | Surgery | Radical esophagectomy |
| DRUG | Immunotherapy | Anti-PD-1/PD-L1 Antibody |
| DRUG | 5-FU Analog based chemotherpay | W1-5 qW or d1-14, q3W according to physician's preference |
| DRUG | Nimotuzumab | 200-400mg, d1,qW |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
- First posted
- 2021-03-30
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04821843. Inclusion in this directory is not an endorsement.